1-32 of 32
Keywords: cardiac hypertrophy
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Clin Sci (Lond) (2022) 136 (22): 1661–1681.
Published: 21 November 2022
...Hajed O. Alharbi; Michelle A. Hardyman; Joshua J. Cull; Thomais Markou; Susanna T.E. Cooper; Peter E. Glennon; Stephen J. Fuller; Peter H. Sugden; Angela Clerk Cardiac hypertrophy is necessary for the heart to accommodate an increase in workload. Physiological, compensated hypertrophy (e.g...
Includes: Supplementary data
Clin Sci (Lond) (2022) 136 (21): 1537–1554.
Published: 10 November 2022
... with isoproterenol displayed a decrease in Set7 activity in the heart. In addition, WT and Set7 KO mice injected with isoproterenol exhibited cardiac hypertrophy. Interestingly, Set7 deletion exacerbated cardiac hypertrophy in response to isoproterenol but attenuated myocardial fibrosis. Echocardiograms revealed...
Includes: Supplementary data
Clin Sci (Lond) (2020) 134 (13): 1843–1857.
Published: 17 July 2020
... ), is dynamically regulated during heart development, is expressed at low levels in embryonic hearts and accumulated at high levels in adult hearts. More interestingly, the lncRNA was down-regulated during cardiac hypertrophy and failure both in mice and humans. Importantly, loss of lncRNA CHAIR has no effects...
Clin Sci (Lond) (2019) 133 (22): 2329–2344.
Published: 28 November 2019
...), and epicardial adipose tissue (EAT) secretome on the development and progression of cardiovascular disease (CVD), with a particular focus on cardiac hypertrophy and fibrosis. Correspondence: Michael Tranter ( trantemc@ucmail.uc.edu ) 25 09 2019 08 11 2019 13 11 2019 © 2019 The Author...
Clin Sci (Lond) (2019) 133 (5): 611–627.
Published: 01 March 2019
...Qing Yu; Wenxin Kou; Xu Xu; Shunping Zhou; Peipei Luan; Xiaopeng Xu; Hailing Li; Jianhui Zhuang; Jun Wang; Yifan Zhao; Yawei Xu; Wenhui Peng Cardiac hypertrophy is a common pathophysiological process in various cardiovascular diseases, which still has no effective therapies. Irisin is a novel...
Includes: Supplementary data
Clin Sci (Lond) (2019) 133 (2): 225–238.
Published: 22 January 2019
..., and GAPDH levels were used to normalize the gene-specific expression levels. Primers used for qPCR are listed in Supplementary Table S3. ADAM17 cardiac hypertrophy cardiomyocytes hESCs rare mutation Tetrology of Fallot Tetralogy of Fallot (TOF) is the most common cyanotic congenital...
Includes: Supplementary data
Clin Sci (Lond) (2018) 132 (11): 1117–1133.
Published: 05 June 2018
...)) or vehicle for 14 days. In contrast with WT rats, the TG rats did not develop cardiac hypertrophy after T3 treatment. Indeed, TG rats displayed reduced systolic blood pressure (SBP) and cardiac hyperdynamic condition induced by hyperthyroidism. Moreover, increased plasma levels of Ang II observed...
Clin Sci (Lond) (2018) 132 (10): 1069–1073.
Published: 25 May 2018
...Luciana A. Pescatore; Francisco R.M. Laurindo Cardiac hypertrophy (CH) is a major independent risk factor for heart failure and mortality. However, therapeutic interventions that target hypertrophy signaling in a load-independent way are unavailable. In a recent issue of Clinical Science (vol. 132...
Clin Sci (Lond) (2018) 132 (6): 685–699.
Published: 30 March 2018
...Zhen-Guo Ma; Xin Zhang; Yu-Pei Yuan; Ya-Ge Jin; Ning Li; Chun-Yan Kong; Peng Song; Qi-Zhu Tang T-cell infiltration and the subsequent increased intracardial chronic inflammation play crucial roles in the development of cardiac hypertrophy and heart failure (HF). A77 1726, the active metabolite...
Includes: Supplementary data
Clin Sci (Lond) (2018) 132 (1): 93–110.
Published: 11 January 2018
... exerts cardioprotective effects against myocardial ischemia/reperfusion (MI/R) injury in normal animals, whether rapamycin-elicited cardioprotection is altered in the presence of LVH has yet to be determined. Pressure overload induced cardiac hypertrophied mice and sham-operated controls were exposed...
Includes: Supplementary data
Clin Sci (Lond) (2017) 131 (24): 2885–2900.
Published: 04 December 2017
...-22) is a critical regulator of cardiac function and targets genes involved in metabolic processes. Previously, we generated miR-22 null mice and we showed that loss of miR-22 blunted cardiac hypertrophy induced by mechanohormornal stress. In the present study, we examined the role of miR-22...
Includes: Supplementary data
Clin Sci (Lond) (2017) 131 (2): 155–158.
Published: 23 December 2016
...Douglas G. Tilley; Abdelkarim Sabri This commentary highlights the research presented by Li et al. [ 15 ]. In this issue of Clinical Science , which demonstrates that dual specific phosphatase 12 (DUSP12), through JNK1/2 inhibition, alleviates cardiac hypertrophy in response to pressure overload...
Clin Sci (Lond) (2017) 131 (2): 141–154.
Published: 23 December 2016
...Wei-ming Li; Yi-fan Zhao; Guo-fu Zhu; Wen-hui Peng; Meng-yun Zhu; Xue-jing Yu; Wei Chen; Da-chun Xu; Ya-wei Xu Pathological cardiac hypertrophy is an independent risk factor of heart failure. However, we still lack effective methods to reverse cardiac hypertrophy. DUSP12 is a member of the dual...
Includes: Supplementary data
Clin Sci (Lond) (2016) 130 (24): 2305–2316.
Published: 10 November 2016
... Mendes; Diego Basile Colugnati; Renata Mazaro-Costa; Carlos Henrique de Castro Previous studies have demonstrated a protective effect of the Ang-(1–7)/Mas receptor axis on pathological cardiac hypertrophy. Also, the involvement of Mas receptor in exercise-induced cardiac hypertrophy has been suggested...
Includes: Supplementary data
Clin Sci (Lond) (2016) 130 (22): 2005–2015.
Published: 06 October 2016
...Ursula Paula Renó Soci; Tiago Fernandes; Valerio Garrone Barauna; Nara Yumi Hashimoto; Gloria de Fátima Alves Mota; Kaleizu Teodoro Rosa; Maria Claudia Irigoyen; Michael Ian Philips; Edilamar Menezes de Oliveira Aerobic exercise-induced cardiac hypertrophy (CH) is a physiological response involving...
Clin Sci (Lond) (2016) 130 (10): 813–828.
Published: 01 April 2016
... (limb girdle muscular dystrophy 2H). However, whether TRIM32 is involved in cardiac hypertrophy induced by biomechanical stresses and neurohumoral mediators remains unclear. We generated mice and isolated NRCMs (neonatal rat cardiomyocytes) that overexpressed or were deficient in TRIM32 to investigate...
Clin Sci (Lond) (2016) 130 (7): 463–478.
Published: 17 February 2016
... has revealed the participation of CXCR3 and its ligands in multiple cardiovascular diseases (CVDs) of different aetiologies including atherosclerosis, hypertension, cardiac hypertrophy and heart failure, as well as in heart transplant rejection and transplant coronary artery disease (CAD). CXCR3...
Clin Sci (Lond) (2014) 127 (1): 1–13.
Published: 10 March 2014
... peptide cardiac hypertrophy gene variant heart failure NT-proANP levels hypertension metabolic syndrome vascular damage The natriuretic peptides family includes three well-characterized hormones: ANP (atrial natriuretic peptide), BNP (brain natriuretic peptide) and CNP (C-type natriuretic...
Clin Sci (Lond) (2014) 126 (4): 275–288.
Published: 14 October 2013
...Hangxiang Zhang; Jing Wu; Hailong Dong; Shaukat A. Khan; Mon-Li Chu; Takeshi Tsuda AngII (angiotensin II) is a potent neurohormone responsible for cardiac hypertrophy, in which TGF (transforming growth factor)-β serves as a principal downstream mediator. We recently found that ablation of fibulin-2...
Clin Sci (Lond) (2009) 116 (5): 365–375.
Published: 02 February 2009
... compilation © 2009 Biochemical Society 2009 cardiac hypertrophy exercise heart failure phosphoinositide 3-kinase (PI3K) protection HF (heart failure) is a debilitating condition in which the ability of the heart to meet systemic demands for oxygenated blood is compromised. Mortality rates...
Clin Sci (Lond) (2008) 114 (12): 699–706.
Published: 14 May 2008
.... Modulating these aberrantly expressed miRNAs has significant effects on cardiac hypertrophy, vascular neointimal lesion formation and cardiac arrhythmias. Identifying the roles of miRNAs and their target genes and signalling pathways in cardiovascular disease will be critical for future research. miRNAs may...
Clin Sci (Lond) (2003) 105 (6): 647–653.
Published: 01 December 2003
... with monocrotaline (60 mg/kg intraperitoneal) or saline, followed with treatment with the selective ET A receptor antagonist LU135252 (LU; 50 mg·kg -1 ·day -1 ) or with saline. After 3 weeks, haemodynamics, cardiac hypertrophy, ET-1 levels and cardiopulmonary ET-receptor-binding profile were evaluated. Monocrotaline...
Clin Sci (Lond) (2002) 103 (s2002): 16S–20S.
Published: 01 September 2002
...Satoshi SAKAI; Takashi MIYAUCHI; Yoko IRUKAYAMA-TOMOBE; Takehiro OGATA; Katsutoshi GOTO; Iwao YAMAGUCHI Endothelin-1 (ET-1) causes cardiac hypertrophy, and ET receptor antagonists inhibit the development of cardiac hypertrophy in vitro and in vivo . Peroxisome proliferator-activated receptor γ...
Clin Sci (Lond) (1998) 95 (3): 261–267.
Published: 01 September 1998
...M. BRAHIMI; B. I. LEVY; M. E. SAFAR; H. DABIRÉ 1. Coronary ischaemic disease and congestive heart failure are the principal causes of mortality in patients with peripheral vascular disease. Whether cardiac hypertrophy is present and even more pronounced in peripheral vascular disease than in other...
Clin Sci (Lond) (1998) 94 (4): 359–365.
Published: 01 April 1998
... by left coronary ligation at 30 days post-surgery and (b) in rats with pressure-related cardiac hypertrophy induced by aortic banding at several time points (0.5, 1 and 4 h, and 1, 4, 7 and 28 days) after surgery. Levels were compared with those in matched sham-operated controls. 3. The mRNA level...
Clin Sci (Lond) (1994) 87 (2): 239–243.
Published: 01 August 1994
... cardiac hypertrophy accompanying hypertension are not affected by growth hormone deficiency. Blood pressure cardiac hypertrophy dwarfism growth hormone insulin-like growth factor-I © 1994 The Biochemical Society and the Medical Research Society 1994 8 10 1993 28 2 1994 17 3...
Clin Sci (Lond) (1993) 84 (5): 531–535.
Published: 01 May 1993
...Tamiko Oka; Hikaru Nishimura; Masakuni Ueyama; Jiro Kubota; Keishiro Kawamura 1. Our aim was to evaluate the effects of an aortocaval fistula (1 mm) on cardiorenal haemodynamics, cardiac hypertrophy and neurohumoral factors in spontaneously hypertensive rats and to compare the results with those...
Clin Sci (Lond) (1992) 82 (1): 25–32.
Published: 01 January 1992
... The Biochemical Society and the Medical Research Society 1992 cardiac hypertrophy left ventricular mass non-linear model Clinical Science (1992) 82, 25-32 (Printed in Great Britain) Model-based determination of cut-off values for left ventricular hypertrophy from echocardiographic myocardial mass data...
Clin Sci (Lond) (1981) 61 (s7): 105s–108s.
Published: 01 December 1981
... to influence significantly the regression of hypertensive left ventricular hypertrophy. © 1981 The Biochemical Society and the Medical Research Society 1981 atenolol cardiac hypertrophy echocardiography hypertension Clinical Science (1981) 61, 105s-108s 105s Factors influencing cardiac...
Clin Sci (Lond) (1981) 61 (3): 265–272.
Published: 01 September 1981
...Ingegerd östman-Smith © 1981 The Biochemical Society and the Medical Research Society 1981 β-adrenoceptor aortic stenosis cardiac hypertrophy coarctation hypertension noradrenaline sympathetic nerves Clinical Science (1981) 61,265-272 265 EDITORIAL REVIEW Cardiac sympathetic...
Clin Sci (Lond) (1980) 59 (s6): 457s–460s.
Published: 01 December 1980
... cardiac hypertrophy hypertension isoprenaline noradrenaline osmotic minipump α- or β-receptor-blocking agents Clinical Science (1980) 5 9 , 4 5 7 ~ 4 6 0 s 457s Effect of P-receptor-blocking agents on cardiovascular structural changes in spontaneous and noradrenaline-induced hypertension in rats Y...
Clin Sci (Lond) (1979) 56 (5): 439–443.
Published: 01 May 1979
...S. Sen; R. C. Tarazi; F. M. Bumpus 1. Angiotensin II (AII) antagonists, namely Sar 1 ,Ile 8 -AII, Sar 1 ,Ala 8 -AII and Sar 1 ,Thr 8 -AII, were administered daily for 4 weeks to normotensive rats to study their effect on cardiac hypertrophy. 2. None of the antagonists altered blood pressure...